Quanterix makes the case with ctDNA in oncology, p-tau217 in Alzheimer’s and a lab model built for longitudinal, regulatory-grade data.
Biomarkers have moved from “nice-to-have” to the backbone of drug development, says Quanterix’s Jorge Marques Signes, who argues they now shape feasibility, timelines and even payer expectations before sponsors commit thousands of patients or years of spend.